Current advance of nanotechnology in diagnosis and treatment for malignant tumors

Signal Transduction and Targeted Therapy, Год журнала: 2024, Номер 9(1)

Опубликована: Авг. 12, 2024

Cancer remains a significant risk to human health. Nanomedicine is new multidisciplinary field that garnering lot of interest and investigation. shows great potential for cancer diagnosis treatment. Specifically engineered nanoparticles can be employed as contrast agents in diagnostics enable high sensitivity high-resolution tumor detection by imaging examinations. Novel approaches labeling are also made possible the use nanoprobes nanobiosensors. The achievement targeted medication delivery therapy accomplished through rational design manufacture nanodrug carriers. Nanoparticles have capability effectively transport medications or gene fragments tissues via passive active targeting processes, thus enhancing treatment outcomes while minimizing harm healthy tissues. Simultaneously, context radiation sensitization photothermal enhance therapeutic efficacy malignant tumors. This review presents literature overview summary how nanotechnology used According oncological diseases originating from different systems body combining pathophysiological features cancers at sites, we most recent developments applications. Finally, briefly discuss prospects challenges cancer.

Язык: Английский

---

Effect of immunotherapy-infusion time of day on survival of patients with advanced cancers: a study-level meta-analysis

ESMO Open, Год журнала: 2024, Номер 9(2), С. 102220 - 102220

Опубликована: Янв. 21, 2024

Background

Immune checkpoint inhibitors (ICIs) have become the standard of care for numerous malignancies. Emerging evidence suggests that time day (ToD) ICI administration could impact outcomes patients with cancer. The consistency ToD effects on efficacy awaits initial evaluation.

Materials and methods

This meta-analysis integrates progression-free survival (PFS) overall (OS) data from studies a defined ‘cut-off' ToD. Hazard ratios (HRs) [95% confidence interval (CI)] an earlier progression or death according to ‘early' ‘late' ICIs were collected each report pooled.

Results

Thirteen involved 1663 (Eastern Cooperative Oncology Group performance status 0-1, 83%; males/females, 67%/33%) non-small-cell lung cancer (47%), renal cell carcinoma (24%), melanoma (20%), urothelial (5%), esophageal (4%). Most received anti-programmed protein 1 death-ligand (98%), small proportion also anti-cytotoxic T-lymphocyte-associated 4 (anti-CTLA-4) (18%). cut-offs 13:00 14:00 (i.e. median infusion time), six studies, 16:00 16:30 reported threshold weaker vaccination responses) seven studies. Pooled analyses revealed early groups had longer OS (HR 0.50, 95% CI 0.42-0.58; P < 0.00001) PFS 0.51, 0.42-0.61; compared late groups.

Conclusions

Patients selected metastatic cancers seemed largely benefit infusions, which is consistent circadian mechanisms in immune-cell functions trafficking. Prospective randomized trials are needed establish recommendations optimal timing ICI-based therapies.

Язык: Английский

---

Development of Polymethine Dyes for NIR‐II Fluorescence Imaging and Therapy

Advanced Healthcare Materials, Год журнала: 2024, Номер 13(16)

Опубликована: Март 5, 2024

Fluorescence imaging in the second near-infrared window (NIR-II) is burgeoning because of its higher fidelity monitoring physiological and pathological processes than clinical visible/the fluorescence imaging. Notably, heavily dependent on agents. So far, indocyanine green, one polymethine dyes, with good biocompatibility renal clearance only dye approved by Food Drug Administration, but it shows relatively low NIR-II brightness. Importantly, tremendous efforts are devoted to synthesizing dyes for preclinically clinically. They have shown feasibility customization structure properties fulfill various needs therapy. Herein, a timely update special focus molecular design strategies fluorescent, photoacoustic, multimodal imaging, offered. Furthermore, progress sensing biomarkers even reporting drug release illustrated. Moreover, imaging-guided therapies summarized regarding chemo-, photothermal, photodynamic, approaches. In addition, artificial intelligence pointed out potential expedite development. This comprehensive review will inspire interest among wide audience offer handbook people an dyes.

Язык: Английский

---

Circadian regulation of cancer stem cells and the tumor microenvironment during metastasis

Nature Cancer, Год журнала: 2024, Номер 5(4), С. 546 - 556

Опубликована: Апрель 23, 2024

Язык: Английский

---

Why does circadian timing of administration matter for immune checkpoint inhibitors’ efficacy?

British Journal of Cancer, Год журнала: 2024, Номер 131(5), С. 783 - 796

Опубликована: Июнь 4, 2024

Abstract Background Tolerability and antitumour efficacy of chemotherapy radiation therapy can vary largely according to their time administration along the 24-h scale, due moderation molecular cellular mechanisms by circadian rhythms. Recent clinical data have highlighted a striking role dosing for cancer immunotherapy, thus calling critical evaluation. Methods Here, we review analyse through which rhythms influence outcomes on ICI therapies. We examine how rhythm disorders affect tumour immune microenvironment, as main mechanism linking clock cycles in ICIs efficacy. Results Real-life from 18 retrospective studies revealed that early time-of-day (ToD) infusion checkpoint inhibitors (ICIs) could enhance progression-free and/or overall survival up fourfold compared late ToD dosing. The involved total 3250 patients with metastatic melanoma, lung, kidney, bladder, oesophageal, stomach or liver 9 countries. Such large consistent differences effects only result previously ignored robust chronobiological mechanism. timing system coordinates cellular, tissue whole-body physiology timescale. Circadian are generated at level involves 15 specific genes. disruption trigger accelerate carcinogenesis, contribute treatment failure, possibly evasion resulting immunosuppressive microenvironment. Conclusions perspective emerging understanding regulation immunity now calls randomised trials establish recommendations personalised chrono-immunotherapies current forthcoming drugs.

Язык: Английский

---

The circadian system, sleep, and the health/disease balance: a conceptual review

Journal of Sleep Research, Год журнала: 2022, Номер 31(4)

Опубликована: Июнь 7, 2022

Summary The field of “circadian medicine” is a recent addition to chronobiology and sleep research efforts. It represents logical step arising from the increasing insights into circadian system its interactions with life in urbanised societies; applying these health/disease balance at home medical practice (outpatient) clinic (inpatient). Despite fast expansion proliferating efforts, medicine lacks formal framework categorise many observations describing among system, sleep, balance. A good allows us then assign them one or more components hypothesised interactions. Such assignments can lead experiments that document causal (rather than correlational) relationships move discovering mechanisms. This review details such proposed for will hopefully trigger discussion our colleagues, so be improved expanded. As basis medicine, we define health” how it links general health. We put context literature examples six domains balance: fertility, cancer, immune mental health, cardiovascular, metabolism.

Язык: Английский

---

Identification of Patients With Ovarian Cancer Experiencing the Highest Benefit From Bevacizumab in the First-Line Setting on the Basis of Their Tumor-Intrinsic Chemosensitivity (KELIM): The GOG-0218 Validation Study

Journal of Clinical Oncology, Год журнала: 2022, Номер 40(34), С. 3965 - 3974

Опубликована: Окт. 17, 2022

In patients with high-grade ovarian cancer, predictors of bevacizumab efficacy in first-line setting are needed. the ICON-7 trial, a poor tumor intrinsic chemosensitivity (defined by unfavorable modeled cancer antigen-125 [CA-125] ELIMination rate constant K [KELIM] score) was predictive biomarker. Only high-risk disease (suboptimally resected stage III, or IV) exhibiting KELIM score < 1.0 had overall survival (OS) benefit from (median: 29.7

Язык: Английский

---

Circadian Regulation of Drug Responses: Toward Sex-Specific and Personalized Chronotherapy

The Annual Review of Pharmacology and Toxicology, Год журнала: 2023, Номер 64(1), С. 89 - 114

Опубликована: Сен. 19, 2023

Today's challenge for precision medicine involves the integration of impact molecular clocks on drug pharmacokinetics, toxicity, and efficacy toward personalized chronotherapy. Meaningful improvements tolerability and/or medications through proper administration timing have been confirmed over past decade immunotherapy chemotherapy against cancer, as well commonly used pharmacological agents in cardiovascular, metabolic, inflammatory, neurological conditions. Experimental human studies recently revealed sexually dimorphic circadian responses. Dedicated randomized clinical trials should now aim to issue recommendations daily medical practice, integrating innovative technologies remote longitudinal monitoring metrics, statistical prediction clock function from single-timepoint biopsies, multiscale biorhythmic mathematical modelling. Importantly, chronofit patients with a robust function, who would benefit most chronotherapy, need be identified. Conversely, nonchronofit could emerging class chronobiotics targeting clock.

Язык: Английский

---

Chronotherapy in Glioblastoma: state of the art and future perspectives

EBioMedicine, Год журнала: 2023, Номер 89, С. 104470 - 104470

Опубликована: Фев. 15, 2023

Язык: Английский

---

Early morning immune checkpoint blockade and overall survival of patients with metastatic cancer: An In-depth chronotherapeutic study

European Journal of Cancer, Год журнала: 2024, Номер 199, С. 113571 - 113571

Опубликована: Янв. 22, 2024

Introduction Recent retrospective studies suggest potential large patient's benefit through proper timing of immune checkpoint blockers (ICB). The association between ICB treatment and patient survival, neoplastic response toxicities was investigated, together with interactions performance status (PS) sex. Methods A cohort patients metastatic or locally advanced solid tumors, who received pembrolizumab, nivolumab, atezolizumab, durvalumab, avelumab, alone concomitant chemotherapy, November 2015 March 2021, at the Centre Leon Bérard (France), retrospectively studied. Results 361 were investigated (80% non-small cell lung cancer patients, mean [SD] age: 63 [ 11 Giacchetti S. Bjarnason G. Garufi C. et al. Phase III trial comparing 4-day chronomodulated therapy versus 2-day conventional delivery fluorouracil, leucovorin, oxaliplatin as first-line chemotherapy colorectal cancer: European Organisation for Research Treatment Cancer Chronotherapy Group. J Clin Oncol Off Am Soc Oncol. 2006; 24: 3562-3569https://doi.org/10.1200/JCO.2006.06.1440 Crossref PubMed Scopus (178) Google Scholar ] years, 39% women, 83% PS0-1 first infusion, 19% chemotherapy). administered from 07:25 to 17:21 optimal morning/afternoon cut-off 11:37. Morning infusions associated increased OS compared afternoon (median 30.3 vs 15.9 months, p=0.0024; HR 1.56 [1.17-2.1], p=0.003). strong PS-timing interaction found (PS0-1 HR=1.53 [1.10-2.12], p=0.011; PS2-3 HR=0.50 [0.25-0.97], p=0.042). displayed 36.7 21.3 p=0.023), partial/complete rate (58% 41%, p=0.027), grade1-3 (49% 34%, p=0.028). Mortality risk ratio worst time-of-day, estimated 13:36 [12:48-14:23], in early morning 5.5-fold ([ 2 Lévi F. Okyar A. Dulong Innominato P.F. Clairambault J. Circadian treatments. Annu Rev Pharmacol Toxicol. 2010; 50: 377-421https://doi.org/10.1146/annurev.pharmtox.48.113006.094626 (331) , 3 Dallmann R. Dosing-Time Makes Poison: Regulation Pharmacotherapy. Trends Mol Med. 2016; 22: 430-445https://doi.org/10.1016/j.molmed.2016.03.004 Abstract Full Text PDF (168) 4 Printezi M.I. Kilgallen A.B. Bond M.J.G. Toxicity efficacy chemotherapy: a systematic review. Lancet 2022; 23: e129-e143https://doi.org/10.1016/S1470-2045(21)00639-2 (26) 5 Zidani Misset J.L. Randomised multicentre chronotherapy oxaliplatin, folinic acid cancer. International Organization Chronotherapy. Lond Engl. 1997; 350: 681-686https://doi.org/10.1016/s0140-6736(97)03358-8 (0) 6 Brienza chronopharmacologic phase II clinical 5-fluorouracil, acid, using an ambulatory multichannel programmable pump. High antitumor effectiveness against Cancer. 1992; 69: 893-900https://doi.org/10.1002/1097-0142(19920215)69:4<893::aid-cncr2820690410>3.0.co;2-x 7 Curé H. Chevalier V. Adenis infusion high-dose fluorouracil l-folinic previously untreated 2002; 20: 1175-1181https://doi.org/10.1200/JCO.2002.20.5.1175 8 Perpoint B. multicenter randomized added fluorouracil-leucovorin 2000; 18: 136-147https://doi.org/10.1200/JCO.2000.18.1.136 9 Ballesta Huang Q. Sex-dependent least toxic irinotecan combined Randomized EORTC 05011 trial. 2020; 9: 4148-4159https://doi.org/10.1002/cam4.3056 (34) 10 Dugué P.A. Sex moderates circadian effects on survival meta-analysis. Ann Eur Med 2012; 3110-3116https://doi.org/10.1093/annonc/mds148 (98) 12 Reck M. Rodríguez-Abreu D. Robinson A.G. Five-Year Outcomes With Pembrolizumab Versus Chemotherapy Metastatic Non-Small-Cell Lung PD-L1 Tumor Proportion Score ≥ 50. 2021; 39: 2339-2349https://doi.org/10.1200/JCO.21.00174 (412) 13 Herbst R.S. Giaccone de Marinis Atezolizumab First-Line PD-L1-Selected Patients NSCLC. N Engl 383: 1328-1339https://doi.org/10.1056/NEJMoa1917346 (830) 14 Zhou Li Wang Z. An Adverse events immunotherapy review network Int Immunopharmacol. 102108353https://doi.org/10.1016/j.intimp.2021.108353 (14) 15 D.Y. Salem J.E. Cohen J.V. Fatal Toxic Effects Associated Immune Checkpoint Inhibitors: Systematic Review Meta-analysis. JAMA 2018; 4: 1721-1728https://doi.org/10.1001/jamaoncol.2018.3923 (1454) 16 Dolladille Ederhy Sassier Inhibitor Rechallenge After Immune-Related Events 6: 865-871https://doi.org/10.1001/jamaoncol.2020.0726 (262) 17 Qian D.C. Kleber T. Brammer Effect time-of-day overall among melanoma USA (MEMOIR): propensity score-matched analysis single-centre, longitudinal study. 1777-1786https://doi.org/10.1016/S1470-2045(21)00546-5 (58) 18 Karaboué Collon Pavese I. Time-Dependent Efficacy Nivolumab: Pilot Study Cancers. 14: 896https://doi.org/10.3390/cancers14040896 (23) 19 Cortellini Barrichello A.P.C. Alessi study pembrolizumab patterns outcomes non-small-cell too soon promote infusions. 33: 1202-1204https://doi.org/10.1016/j.annonc.2022.07.1851 (4) 20 Rousseau Tagliamento Auclin E. Clinical by inhibitors Oxf 1990. 2023; 182: 107-114https://doi.org/10.1016/j.ejca.2023.01.007 ], p=0.008). Timing differences resulted significant only female (women men: p<0.001 0.4). Conclusions Early OS, response, later within day. Prospective trials are needed confirm this

Язык: Английский

---